Taiho Pharmaceutical Co. Ltd., of Tokyo, and Cullinan Oncology LLC, of Cambridge, Mass., inked a deal to develop TAS-6417, an EGFR tyrosine kinase inhibitor discovered by Taiho. Under the terms, Taiho will grant an exclusive global license, excluding Japan, for the development and commercialization of TAS-6417 to Cullinan Pearl, a newly formed U.S.-based company under the Cullinan Oncology umbrella.